LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Herpes Simplex Virus Molecular Test Receives US FDA Clearance

By LabMedica International staff writers
Posted on 03 Mar 2015
A leading developer of multiplex polymerase chain reaction technology has announced that its herpes simplex virus (HSV) types 1 and 2 assay has been granted 510 (k) market clearance.

The tests are based on its breakthrough technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis and the tests are the most comprehensive and cost-effective multiplexed polymerase chain reaction (PCR) molecular assays for infectious disease in the industry.

Image: A three dimensional illustration of the herpes simplex virus (HSV) (Photo courtesy of Bryan Brandenburg).
Image: A three dimensional illustration of the herpes simplex virus (HSV) (Photo courtesy of Bryan Brandenburg).

The US Food and Drug Administration (FDA, Silver Springs, MD, USA) has granted the market clearance for the high multiplex real-time quantitative PCR known as TOCE technology, that enables confirmation of multiple (five or more) target genetic detection and genetic variation. TOCE can implement qualitative test that analyzes multiple clinical samples and quantitative analysis bases on Cyclic Catcher Melting Temperature Analysis (cyclic-CMTA).

The company producing the approved HSV types 1 and 2 assay is Seegene (Seoul, Republic of Korea) that uses the Allplex tests which are based on its breakthrough MuDT technology. This powerful technology is capable of simultaneous quantification and detection/discrimination of multiple targets in a single channel without additional melting curve analysis after amplification step. It satisfies the growing demands for both high multiplexing and quantification in a single assay by overcoming the current technology barrier of “one channel, only one cycle threshold (Ct).” MuDT technology opens a new chapter of PCR-based molecular diagnostics to deliver a more comprehensive and actionable diagnostic information.

Jong-Yoon Chun, PhD, founder, CTO and CEO of Seegene, said, “This is an important milestone in support of our planned entry into the USA, the largest molecular diagnostic market in the world. After more than 10 years of extensive efforts to continually develop and commercialize novel technologies to surpass the capabilities of real-time PCR, we successfully invented MuDT technology, an ultimate multiplex real-time PCR technology that marks a new era in the molecular diagnostics industry. Through the US FDA approval, Seegene now intends to actively enhance its leadership in the multiplex real-time PCR diagnostic testing market.”

Related Links:
US Food and Drug Administration 
Seegene 



New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Capillary Blood Collection Tube
IMPROMINI M3

Latest Microbiology News

Saliva Test Detects Implant-Related Microbial Risks
02 Mar 2015  |   Microbiology

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
02 Mar 2015  |   Microbiology

Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
02 Mar 2015  |   Microbiology